SCHEMBL6918405

SCHEMBL6918405

COc1c(Cl)ncnc1-c1ccc(C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 4/20 0.36
NPSR1 Q6W5P4 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
MAPT P10636 1/20 0.36
DHPS P49366 1/20 0.36
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
KDM4E B2RXH2 1/20 0.35
EGFR P00533 1/20 0.34
TUBB4A P04350 1/20 0.34
TUBB P07437 1/20 0.34
TUBA3C P0DPH7 1/20 0.34
TUBA1B P68363 1/20 0.34
TUBA4A P68366 1/20 0.34
TUBB4B P68371 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23147071 0.85 KMO (0.43) KMOKMT2ANPSR1NPC1RAB9A
SCHEMBL4720698 0.81 ALOX5AP (0.40) KMOKMT2ANPSR1NPC1RAB9A
SCHEMBL6918947 0.80 CYP19A1 (0.40) L3MBTL1NPSR1NPC1RAB9AMAPT
SCHEMBL5646419 0.78 L3MBTL1 (0.46) KMOL3MBTL1KMT2ATDP1ALDH1A1
SCHEMBL18985690 0.78 KMO (0.46) KMOKMT2ANPC1RAB9ATDP1
SCHEMBL1232782 0.77 HTT (0.42) L3MBTL1KMT2ANPSR1NPC1RAB9A
SCHEMBL9609002 0.76 L3MBTL1 (0.49) L3MBTL1KMT2ANPC1RAB9ATDP1
SCHEMBL288911 0.74 ALDH1A1 (0.44) KMOKMT2ANPSR1NPC1RAB9A
SCHEMBL9607644 0.74 KMO (0.43) KMOALDH1A1KDM4E
SCHEMBL5647677 0.72 ALDH1A1 (0.50) L3MBTL1KMT2ANPSR1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462123-B1 4,5,6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2013-10-02 EP disclosed
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2012-05-31 US disclosed
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2012-05-31 US disclosed
WO-2011017296-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS SCHERING CORPORATION (US) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS F9, F8, F12 KMO 2600/4885L3MBTL1 4611/4885KMT2A 2705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.